 LOS ANGELES--BUSINESS WIRE--- CDXC COVID19research--ChromaDex Corp. NASDAQ: CDXC today announced results from the study Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19 were published Feb. 20 on medRxiv, a preprint publication website. The Phase 3 study demonstrated that patients with mild-to-moderate COVID-19 receiving standard of care experienced a 3.5 day reduction in recovery time when receiving an added nutritional protocol. Aimed at improving mitochondrial function, the proto 